Adverse effects of dopamine potentiation by long-term treatment with selegiline.
Identifieur interne : 003572 ( PubMed/Checkpoint ); précédent : 003571; suivant : 003573Adverse effects of dopamine potentiation by long-term treatment with selegiline.
Auteurs : Susan Hollán [Hongrie] ; Lászl Vécsei ; Kálmán MagyarSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Adolescent, Adult, Anemia, Hemolytic, Congenital (enzymology), Anemia, Hemolytic, Congenital (genetics), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Baclofen (adverse effects), Baclofen (therapeutic use), Basal Ganglia (drug effects), Basal Ganglia Diseases (drug therapy), Basal Ganglia Diseases (enzymology), Basal Ganglia Diseases (genetics), Blood Platelets (enzymology), Drug Therapy, Combination, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (etiology), Dystonia Musculorum Deformans (drug therapy), Dystonia Musculorum Deformans (enzymology), Dystonia Musculorum Deformans (genetics), Female, Genotype, Glyceraldehyde-3-Phosphate Dehydrogenases (deficiency), Glyceraldehyde-3-Phosphate Dehydrogenases (genetics), Heterozygote Detection, Humans, Long-Term Care, Male, Middle Aged, Monoamine Oxidase (blood), Monoamine Oxidase (genetics), Monoamine Oxidase Inhibitors (adverse effects), Monoamine Oxidase Inhibitors (therapeutic use), Nerve Tissue Proteins (genetics), Neurologic Examination (drug effects), Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Nuclear Proteins (genetics), Polymerase Chain Reaction, Proteins (genetics), Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (etiology), Reference Values, Selegiline (adverse effects), Selegiline (therapeutic use), Trinucleotide Repeats.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Baclofen, Monoamine Oxidase Inhibitors, Neuroprotective Agents, Selegiline.
- chemical , blood : Monoamine Oxidase.
- chemical , deficiency : Glyceraldehyde-3-Phosphate Dehydrogenases.
- diagnosis : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- drug effects : Basal Ganglia, Neurologic Examination.
- drug therapy : Basal Ganglia Diseases, Dystonia Musculorum Deformans.
- enzymology : Anemia, Hemolytic, Congenital, Basal Ganglia Diseases, Blood Platelets, Dystonia Musculorum Deformans.
- etiology : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- genetics : Anemia, Hemolytic, Congenital, Basal Ganglia Diseases, Dystonia Musculorum Deformans, Glyceraldehyde-3-Phosphate Dehydrogenases, Monoamine Oxidase, Nerve Tissue Proteins, Nuclear Proteins, Proteins.
- chemical , therapeutic use : Antiparkinson Agents, Baclofen, Monoamine Oxidase Inhibitors, Neuroprotective Agents, Selegiline.
- Adolescent, Adult, Drug Therapy, Combination, Female, Genotype, Heterozygote Detection, Humans, Long-Term Care, Male, Middle Aged, Polymerase Chain Reaction, Reference Values, Trinucleotide Repeats.
Abstract
A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.
DOI: 10.1002/mds.10641
PubMed: 14743370
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14743370Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse effects of dopamine potentiation by long-term treatment with selegiline.</title><author><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cell Biology, National Blood Transfusion Service, Budapest, Hungary. hollan@ella.hu</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Cell Biology, National Blood Transfusion Service, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name></author><author><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14743370</idno><idno type="pmid">14743370</idno><idno type="doi">10.1002/mds.10641</idno><idno type="wicri:Area/PubMed/Corpus">003567</idno><idno type="wicri:Area/PubMed/Curation">003567</idno><idno type="wicri:Area/PubMed/Checkpoint">003572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adverse effects of dopamine potentiation by long-term treatment with selegiline.</title><author><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cell Biology, National Blood Transfusion Service, Budapest, Hungary. hollan@ella.hu</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Cell Biology, National Blood Transfusion Service, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name></author><author><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anemia, Hemolytic, Congenital (enzymology)</term><term>Anemia, Hemolytic, Congenital (genetics)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Baclofen (adverse effects)</term><term>Baclofen (therapeutic use)</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia Diseases (drug therapy)</term><term>Basal Ganglia Diseases (enzymology)</term><term>Basal Ganglia Diseases (genetics)</term><term>Blood Platelets (enzymology)</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dystonia Musculorum Deformans (drug therapy)</term><term>Dystonia Musculorum Deformans (enzymology)</term><term>Dystonia Musculorum Deformans (genetics)</term><term>Female</term><term>Genotype</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases (deficiency)</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases (genetics)</term><term>Heterozygote Detection</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase (blood)</term><term>Monoamine Oxidase (genetics)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Nerve Tissue Proteins (genetics)</term><term>Neurologic Examination (drug effects)</term><term>Neuroprotective Agents (adverse effects)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Nuclear Proteins (genetics)</term><term>Polymerase Chain Reaction</term><term>Proteins (genetics)</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (etiology)</term><term>Reference Values</term><term>Selegiline (adverse effects)</term><term>Selegiline (therapeutic use)</term><term>Trinucleotide Repeats</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Baclofen</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Monoamine Oxidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glyceraldehyde-3-Phosphate Dehydrogenases</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Dystonia Musculorum Deformans</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Anemia, Hemolytic, Congenital</term><term>Basal Ganglia Diseases</term><term>Blood Platelets</term><term>Dystonia Musculorum Deformans</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Anemia, Hemolytic, Congenital</term><term>Basal Ganglia Diseases</term><term>Dystonia Musculorum Deformans</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases</term><term>Monoamine Oxidase</term><term>Nerve Tissue Proteins</term><term>Nuclear Proteins</term><term>Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Baclofen</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Genotype</term><term>Heterozygote Detection</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Polymerase Chain Reaction</term><term>Reference Values</term><term>Trinucleotide Repeats</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14743370</PMID><DateCreated><Year>2004</Year><Month>01</Month><Day>26</Day></DateCreated><DateCompleted><Year>2004</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Adverse effects of dopamine potentiation by long-term treatment with selegiline.</ArticleTitle><Pagination><MedlinePgn>107-9</MedlinePgn></Pagination><Abstract><AbstractText>A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.</AbstractText><CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollán</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cell Biology, National Blood Transfusion Service, Budapest, Hungary. hollan@ella.hu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vécsei</LastName><ForeName>László</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Magyar</LastName><ForeName>Kálmán</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C086055">HTT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.2.1.-</RegistryNumber><NameOfSubstance UI="D005987">Glyceraldehyde-3-Phosphate Dehydrogenases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>H789N3FKE8</RegistryNumber><NameOfSubstance UI="D001418">Baclofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000745">Anemia, Hemolytic, Congenital</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001418">Baclofen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001480">Basal Ganglia Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001792">Blood Platelets</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004422">Dystonia Musculorum Deformans</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005987">Glyceraldehyde-3-Phosphate Dehydrogenases</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000172">deficiency</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006580">Heterozygote Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008134">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008995">Monoamine Oxidase</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008996">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009687">Nuclear Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011506">Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011605">Psychoses, Substance-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018911">Trinucleotide Repeats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14743370</ArticleId><ArticleId IdType="doi">10.1002/mds.10641</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Hongrie</li></country><region><li>Hongrie centrale</li></region><settlement><li>Budapest</li></settlement></list><tree><noCountry><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name></noCountry><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14743370
|texte= Adverse effects of dopamine potentiation by long-term treatment with selegiline.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14743370" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |